<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03917940</url>
  </required_header>
  <id_info>
    <org_study_id>omega 3 in diabetics type 2</org_study_id>
    <nct_id>NCT03917940</nct_id>
  </id_info>
  <brief_title>Omega 3 Fatty Acids on Serum Irisin and Sirtuin-1 in Type 2 Diabetic Mellitus Patients Treated With Glimepiride</brief_title>
  <official_title>The Effect of Omega 3 Fatty Acids on Blood Glucose, Lipids Profile, Serum Irisin and Sirtuin-1 in Type 2 Diabetic Mellitus Patients Treated With Glimepiride</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damanhour University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      study the effect of omega 3 fatty acids on blood glucose, lipids profile, serum Irisin and
      sirtuin-1 in type 2 diabetic mellitus patients treated with glimepiride.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Approval will be obtained from Research Ethics Committee of Faculty of Pharmacy,
           Damanhour University

        2. All Participants agreed to take part in this clinical study and provide informed
           consent.

      Methodology

        -  The study will be conducted in 70 patients who are aged 30-60 years old with type 2
           diabetes mellitus for at least 2 years. The patients will be assigned into two groups
           (Omega - 3/glimepiride, n=35; glimepiride, n=35).

        -  Serum Irisin, sirtuin-1, Hb A1C, Fasting blood sugar (FBS), Lipid profile, Fasting
           insulin, HOMA-IR and Atherogenic index of plasma (AIP) will be measured at the beginning
           and after 12 weeks of intervention.

        -  Anthro-pometric parameters including Weight and height to calculate body mass index will
           be measured at the beginning and after intervention.

        -  past medical history and medication history will be documented.

        -  Each subject in the test group will receive a total dose of 3000 mg of omega-3 fatty
           acids per day in the form of three capsules along with a glimepiride tablet to be taken
           once daily, while each subject in the other group will receive glimepiride tablet to be
           taken once daily for 12 weeks.

        -  Venous blood samples will be obtained from patients at the beginning and after 12 weeks
           of intervention.

        -  A commercially available enzyme-linked immuno-sorbent assay kits will be used for the
           measurement of Irisin and sirtuin-1.

        -  The patients will be advised not to change their usual diet, drug regimen and physical
           activity levels throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2019</start_date>
  <completion_date type="Actual">May 10, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The patients will be divided into two groups: group 1 treated with (Omega - 3 and glimepiride, n=35). group 2 treated with glimepiride alone, n=35).</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum Irisin concentration (ng/ml)</measure>
    <time_frame>three months</time_frame>
    <description>Myokines have anti- inflammatory properties</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum sirtuin-1 concentration (ng/ml)</measure>
    <time_frame>three months</time_frame>
    <description>class III protein deacetylase that is associated with aging, inflammation and CVD</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Diabetic Patients</condition>
  <arm_group>
    <arm_group_label>Omega 3 + glimepiride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>group 1: 35 patients treated with (Omega - 3 1000mg / day oral plus glimepiride 2mg or 3mg /day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>group 2: 35 patients treated with glimepiride 2mg or 3mg /day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega 3 fatty acids 1000 mg per day + glimepiride 2 mg or 3 mg oral</intervention_name>
    <description>Omega 3 fatty acids 1000 mg per day oral</description>
    <arm_group_label>Omega 3 + glimepiride</arm_group_label>
    <other_name>Omega three</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>glimepiride 2 mg or 3 mg per day oral</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Amaryl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  70 Adult patients aged 30-60 years old with type 2 diabetes mellitus treated with
             glimepiride.

          -  glycated hemoglobin percent greater than 7%.

          -  body mass index between 25 and 35 kg/m2.

          -  Patients who are not consuming omega-3 fatty acids, supplements or any pharmaceutical
             products that may interact with their lipid profile.

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  Have gastrointestinal disorders that interfere with the bowel function

          -  patients with severe hepatic, renal, inflammatory and thyroid diseases.

          -  insulin therapy.

          -  Have diabetes complications including micro and macrovascular complications.

          -  Alcoholics and patients with past history of drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maged W Helmy, Ass. Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Pharmacology &amp; Toxicology department- faculty of pharmacy- Damanhour University.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Damanhour Medical National Institute</name>
      <address>
        <city>Damanhūr</city>
        <state>El-Bahairah</state>
        <zip>31527</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Aghasi M, Ghazi-Zahedi S, Koohdani F, Siassi F, Nasli-Esfahani E, Keshavarz A, Qorbani M, Khoshamal H, Salari-Moghaddam A, Sotoudeh G. The effects of green cardamom supplementation on blood glucose, lipids profile, oxidative stress, sirtuin-1 and irisin in type 2 diabetic patients: a study protocol for a randomized placebo-controlled clinical trial. BMC Complement Altern Med. 2018 Jan 17;18(1):18. doi: 10.1186/s12906-017-2068-6.</citation>
    <PMID>29343256</PMID>
  </results_reference>
  <results_reference>
    <citation>Lluís L, Taltavull N, Muñoz-Cortés M, Sánchez-Martos V, Romeu M, Giralt M, Molinar-Toribio E, Torres JL, Pérez-Jiménez J, Pazos M, Méndez L, Gallardo JM, Medina I, Nogués MR. Protective effect of the omega-3 polyunsaturated fatty acids: Eicosapentaenoic acid/Docosahexaenoic acid 1:1 ratio on cardiovascular disease risk markers in rats. Lipids Health Dis. 2013 Oct 1;12:140. doi: 10.1186/1476-511X-12-140.</citation>
    <PMID>24083393</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>April 14, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2019</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irisin</keyword>
  <keyword>sirtuin-1</keyword>
  <keyword>Omega 3 fatty acids</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

